Cargando…
Coagulopathy and Plausible Benefits of Anticoagulation Among COVID-19 Patients
The exceptional outbreak of COVID-19 pandemic has let the scientific community to work closely and quickly learnt things in a very short period of time. This has let us recognize that thromboembolic complications are responsible for morbidity and mortality among the COVID-19 infected patients. Avail...
Autores principales: | Ahmed, Syed Imran, Khan, Shahzad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mosby-Year Book
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320667/ https://www.ncbi.nlm.nih.gov/pubmed/32703535 http://dx.doi.org/10.1016/j.cpcardiol.2020.100648 |
Ejemplares similares
-
Covid-19-induced coagulopathy and observed benefits with anticoagulation
por: Karimzadeh, Sedighe, et al.
Publicado: (2020) -
Coagulopathy in COVID-19 and anticoagulation clinical trials
por: Zhang, Heng, et al.
Publicado: (2022) -
COVID-19 Coagulopathy: Current knowledge and guidelines on anticoagulation
por: Salabei, Joshua K, et al.
Publicado: (2021) -
COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation
por: Miesbach, Wolfgang, et al.
Publicado: (2020) -
Monitoring of COVID-19-Associated Coagulopathy and Anticoagulation with Thromboelastometry
por: Katz, Daniel, et al.
Publicado: (2021)